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The huge majority of myeloma cell lines express TNFR2 while a substantial subset of them failed to show TNFR1 expression.
Stimulation of TNFR1 in the TNFR1-expressing subset of MM cell lines had no or only a very mild effect on cellular viability.
Surprisingly, however, TNF stimulation enhanced cell death induction by CD95L and attenuated the apoptotic effect of TRAIL.
The contrasting regulation of TRAIL- and CD95L-induced cell death by TNF could be traced back to the concomitant NFjB-
mediated upregulation of CD95 and the antiapoptotic FLIP protein. It appeared that CD95 induction, due to its strength,
overcompensated a rather moderate upregulation of FLIP so that the net effect of TNF-induced NFjB activation in the context of
CD95signalingispro-apoptotic.TRAIL-inducedcelldeath,however,wasantagonizedinresponsetoTNFbecauseinthiscontext
only the induction of FLIP is relevant. Stimulation of TNFR2 in myeloma cells leads to TRAF2 depletion. In line with this, we
observed cell death induction in TNFR1-TNFR2-costimulated JJN3 cells. Our studies revealed that the TNF-TNF receptor system
adjusts the responsiveness of the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms that generate a highly
context-dependent net effect on myeloma cell survival.
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Multiple myeloma is the consequence of malignant transfor-
mation of terminally differentiated antibody producing B-cells.
Myeloma cells predominantly reside in the bone marrow
where they trigger the formation of an osteoclastic micro-
environment, eventually leading to bone destruction and
associated therewith displacement of normal hematopoi-
esis.
1,2 Two seminal studies demonstrated that about 80%
of primary myeloma samples display a gene expression
signature characteristic of transcription factors of the nuclear
factorkB (NFkB)family, andidentiﬁedmutationsindicative for
cell autonomous activation of NFkB signaling in about 20% of
myeloma cases.
3,4 NFkBs act as homo- or heterodimers and
accomplish pivotal functions in development, cell growth, cell
survival and particularly in immune regulation. The activity of
NFkB transcription factors is held in check by intermolecular
interaction with inhibitor of kB( I kB) proteins or by intramole-
cular interaction with an IkB-related domain both resulting in
masking of the nuclear localization sequence of NFkBs.
5,6
Inducible proteolysis/processing of IkB proteins (or IkB-like
domains) thus represents the central bottleneck in NFkB
activation. It takes place by two distinct routes: the classical
(canonical) and the alternative (non-canonical) NFkB path-
way.
5,6 In the classical pathway, receptor induced activation
of E3 ligases of the TNF receptor-associated factor (TRAF)
family and TRAF-associated kinases trigger activation of the
IkB kinase (IKK) complex. The latter in turn entails ubiquitina-
tion and subsequent degradation of IkB proteins.
5,6 In
contrast, activation of the alternative NFkB signaling pathway
is independent of the IKK complex and instead relies on
receptor-induced deviation/degradation of TRAF2 and
TRAF3. The latter two in concert with cIAP1/2 are responsible
for constitutive degradation of the MAP3K NIK.
5,6 Receptor-
induced degradation of TRAF2 and TRAF3 thus results in NIK
accumulation. NIK in turn stimulates the IKK1 kinase, which
then phosphorylates p100, the precursor of the NFkB family
member p52 which contains an IkB-like inhibitory domain.
Phosphorylation of p100 results in proteasomal destruction of
the inhibitory domain by limited processing of the molecule
resulting in active p52-containing NFkBs.
5,6 The classical
NFkB pathway is stimulated by a wide variety of cellular
stressors (e.g. PAMPs, UV and irradiation) and members of
the Toll-like and the TNF receptor families. One of the
strongest, best investigated and most widely distributed
activators of the classical NFkB pathway is TNFR1.
7 In
contrast to the classical NFkB pathway, the alternative NFkB
pathway is stimulated by a rather limited set of inducers most
of which belong to the TNF receptor family.
5,6 Notably,
TNFR2, the second receptor of TNF is a comparably weak
trigger of classical NFkB signaling but is able to induce the
alternative NFkB pathway.
8 TNF, like most other members of
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www.nature.com/cddisthe TNF ligand family, is a homotrimeric type II transmem-
brane protein from which soluble trimers can be released by
proteolytic processing.
9 It is worth mentioning that both TNF
receptors are robustly activated by membrane TNF while
soluble TNF predominantly stimulates TNFR1 despite binding
to TNFR2.
9 Thus, the availability of TNFR1, TNFR2 and of
soluble and membrane TNF in sum determines the activity of
the classical and alternative pathway in situations of TNF
exposure.
In view of the relevance of the NFkB system for myeloma
cells and the fact that NFkBs regulate a variety of survival
genes, we investigated in this study whether and how
TNF and its receptors regulate the apoptotic sensitivity of
myeloma cells.
Results
TNF receptor expression in multiple myeloma. FACS
analysis showed that with exception of U266 all investigated
myeloma cell lines express TNFR2 on their cell surface
(Figure 1a). Cell surface expression of TNFR1 was more
heterogeneous yielding clear staining only in 3 out of 10 cell
lines (MM.1S, RPMI8226 and KMS-12-BM; Figure 1a). Using
a highly sensitive ligand-binding assay with a Gaussia
princeps luciferase fusion protein of the TNFR1-speciﬁc
TNF mutant 32W/86T,
10 we were able to detect signiﬁcant
TNFR1 expression in ﬁve additional cell lines (U266, OPM2,
KMS-11, INA6 and JJN3) while even with this assay there
was no evidence for TNFR1 expression in AMO1 and L363
(Figure 1b). Binding studies with a Gaussia princeps
luciferase fusion protein of the TNFR2-speciﬁc TNF mutant
143N/145R
10 conﬁrmed the lack of TNFR2 expression in
U266 cells as well as expression of this receptor on all the
other cell lines (Figure 1b). In the three cell lines where
TNFR1 expression was already evident by FACS analysis
and also in two of the four cell lines (OPM2 and INA6) where
TNFR1 expression was only evident by the more sensitive
binding studies, stimulation with TNFR1-speciﬁc Flag-
TNF(32W/86T) resulted in robust activation of the classical
NFkB pathway in terms of phosphorylation and degradation
of IkBa. Albeit very weak, there was also in half of the cell
lines activation of the classical NFkB pathway upon
stimulation with a non-americ form of the TNFR2-speciﬁc
TNF mutant 143N/145R that mimics the activity of
membrane TNF on this receptor (Figure 2a).
8 Indeed, while
induction of NFkB-regulated factors such as RelB, TRAF1
and p100 was readily observable in western blot analysis
of TNFR1-stimulated cells, only one of ﬁve analyzed cell
lines showed a corresponding TNFR2-induced response
(Figure 2b). The lower or even missing capability of TNFR2
to trigger the classical NFkB pathway corresponds to former
reports demonstrating that TNFR1 is superior to TNFR2 in
activation of this response and that the latter depends on the
presence of the highly regulated TRAF1 protein to elicit an
optimal response.
8,11
TNF differentially regulates TRAIL- and CD95L-induced
cell death in myeloma cells. A major effect of activation of
transcription factors of the NFkB family is the transcriptional
upregulation of survival genes.
12 To reveal a potential
protective effect of TNFR1-mediated NFkB activation on
myeloma cells, we primed the three highly TNFR1
responsive myeloma cell lines identiﬁed above (MM.1S,
RPMI8226 and KMS-12-BM) with soluble TNF and
challenged the cells then for 24h with TRAIL and CD95L
that stimulate the death receptors TRAILR1, TRAILR2 and
CD95 as well as with bortezomib (proteasome inhibitor),
NVP-AUY922 (HSP90 inhibitor) and the Akt inhibitor Akti-1/2.
Stimulation of the death receptor TNFR1 alone led to no or
only marginal cell death (Figure 3a), whereas exclusive
stimulation with either TRAIL or CD95L resulted in almost
complete killing of myeloma cells (Figures 3b and c). Priming
of myeloma cells with TNF had no or only a marginal effect
on cell death-induction by the three pharmacological
inhibitors suggesting that activation of the classical NFkB
pathway does not interfere with the anti-myeloma effect of
these clinical and preclinical drugs. TNF priming, however,
exerted opposing effects on TRAIL- and CD95L-induced cell
death of MM.1S and RPMI8226 cells (Figures 3c and d). In
these cell lines there was a strong enhancement of CD95L-
induced cell death upon TNF priming while TRAIL-induced
cell death was reduced (Figures 3c and d). In the third cell
line, KMS-12-BM, there was a moderate sensitizing effect of
TNF on both TRAIL- and CD95L-induced cell death
(Figure 3b). Because CD95 and the TRAIL death receptors
utilize the same receptor-associated mechanisms to induce
cell death,
13 the opposing modulation of their cytotoxic
effects by TNF observed in MM.1S and RPMI8226 cells was
surprising and therefore investigated in more detail.
TNF sensitizes myeloma cells for CD95L-induced cell
death by TNFR1-induced IKK2-mediated upregulation of
CD95. CD95 and the TRAIL death receptors trigger cell
death not only via caspase-8-mediated activation of the
intrinsic apoptotic pathway, but also by the virtue of caspase-
8 activity-independent induction of necrosis via the receptor-
associated serine/threonine kinase RIP1.
14 We therefore
proved ﬁrst whether CD95L and TRAIL utilize the same
molecular mechanisms to initiate MM cell death by help of
the caspase inhibitor zVAD and the RIP1 inhibitor
necrostatin-1. Treatment with the caspase inhibitor zVAD
alone was fully sufﬁcient to rescue MM.1S cells from TRAIL-
and CD95L-induced cell death, irrespective of TNF priming
(Figure 4a). In the case of RPMI8226 cells, zVAD treatment
only partly rescued cells from death ligand-induced
apoptosis. Addition of necrostatin-1 further improved the
protective effect of zVAD in RPMI8226 cells indicating that
these cells principally respond with apoptosis and with
necrosis toward death receptor activation (Figure 4a).
Again TNF priming showed no effect on the quality of cell
death induced by TRAIL and CD95L, making it unlikely that
the differential effect of TNF priming is related to the
utilization of different death pathways by CD95 and the
TRAIL death receptors. An important receptor proximal factor
determining cellular sensitivity for the extrinsic pathway is cell
surface expression of the death receptors. FACS analysis
showed no signiﬁcant changes in TRAIL receptor expression
but revealed a pronounced upregulation of cell surface-
expressed CD95 in the TNF-primed cells (Figure 4b).
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Cell Death and DiseaseIncreased cell surface expression of CD95 was also mirrored
by increased amounts of CD95, FADD and caspase-8
present in Fc-CD95L immunoprecipitates (Figure 4c). Of
note, recruitment of the antiapoptotic protein FLIP was also
increased, but this effect appeared to be overcompensated
by the concomitantly enhanced recruitment of FADD and
caspase-8 (Figure 4c). Soluble TNF predominantly acts via
TNFR1.
15,16 The effects of priming with soluble TNF on
Figure 1 TNFR1 and TNFR2 expression in multiple myeloma cell lines. (a) Cell surface expression of TNFR1 and TNFR2 of the indicated cell lines was analyzed by ﬂow
cytometry using phycoerythrin-conjugated antibodies. (b) Cells (3 10
6) of the various cell lines were preincubated in triplicates with 10mg/ml of the TNFR1-speciﬁc mAb
H398 or a mixture of 3mg/ml Flag-TNC-scTNF(143N/145R) and 3mg/ml Flag-TNF for 1h on ice or left untreated. Cells were then incubated with Gaussia princeps luciferase
fusion proteins of TNFR1- (GpL-Flag-TNC-TNF(32W/86T), 200ng/ml) and TNFR2-speciﬁc (GpL-Flag-TNC-scTNF(143N/145R), 100ng/ml) TNF mutants for an additional
hour. After removal of unbound ligand, cell-associated luciferase activity was determined using a commercially available luciferase assay. The difference in cell-associated
luciferaseactivitybetweensamplesonlytreatedwiththeGaussiaprincepsluciferasefusionproteinsandthecorrespondingsamplespreincubatedwithH398ortheFlag-TNC-
scTNF(143N/145R)/Flag-TNF mixture, gives the speciﬁc binding. Please note the different scales of the y-axes for TNFR1 and TNFR2 binding
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Cell Death and DiseaseCD95L- and TRAIL-induced cell death should therefore be
due to activation of TNFR1. To conﬁrm this by an
independent experimental approach, we used TNFR1- and
TNFR2-speciﬁc activators for myeloma cell priming.
For selective stimulation of TNFR1 we used Flag-
TNF(32W/86T), and for triggering of TNFR2 we used again
Figure 2 TNFR1 and TNFR2 activate the classical NFkB pathway in myeloma cells. (a) The indicated cell lines were stimulated with 200ng/ml Flag-TNF(32W/86T) or
200ng/ml of Flag-TNC-scTNF(143N/145R) for 0, 3, 10 and 30min. Activation of the classical NFkB pathway was monitored by preparing whole-cell lysates that were
subjected to western blot analysis using antibodies recognizing phospho-IkBa and IkBa. Detection of tubulin served as a loading control. (b) Cells were stimulated with
200ng/ml Flag-TNF(32W/86T) and 200ng/ml of Flag-TNC-scTNF(143N/145R) for 24h, and whole-cell lysates were analyzed by western blotting for the expression of the
indicated proteins
TNF and the extrinsic apoptotic pathway in myeloma cells
H Rauert et al
4
Cell Death and Diseasethe TNFR2-speciﬁc membrane TNF-mimicking non-americ
variant Flag-TNC-scTNF(143N/145R). Priming of MM.1S
and RPMI8226 cells with the TNFR1-speciﬁc variant of
soluble TNF elicited the same effect on TRAIL- and CD95L-
induced apoptosis and receptor expression as wild-type TNF
(Figures 4b and 5a,b). In contrast, the TNFR2-speciﬁc non-
americ TNF mutant showed no effect on apoptosis induction
and CD95 expression (Figures 5a and b). To further verify
Figure 3 TNF priming has opposing effects on CD95L- and TRAIL-induced cell death in myeloma cells. (a) MM.1S, RPMI8226 and KMS-12-BM cells were challenged in
threeindependent experiments in triplicatesin 96-well plates with 50ng/ml TNF(open bars) or remaineduntreated (ﬁlled bars),and viability was determinedafter 24 and 48h
using the MTT assay. (b) TNF-primed (50ng/ml, 18h; open bars) and untreated cells (ﬁlled bars) were treated for 24h with TRAIL (MM.1S and RPMI8226: 100ng/ml; KMS-
12-BM: 200ng/ml), Fc-CD95L (MM.1S: 2.5ng/ml; RPMI8226: 10ng/ml; KMS-12-BM: 1ng/ml), Akti-1/2 (MM.1S: 10mM; RPMI8226 and KMS-12-BM: 50mM), NVP-AUY922
(MM.1S: 400nM; RPMI8226 and KMS-12-BM: 1000nM) and bortezomib (MM.1S: 5nM; RPMI8226 and KMS-12-BM: 20nM). Viability was again determined by the MTT
assay. (c) Cells were primed in 96-well plates (triplicates) with TNF (50ng/ml, 18h) and were then challenged for an additional day with the indicated concentration of TRAIL
andFc-CD95L,andﬁnallyviabilitywasdeterminedwiththeMTTassay.(d)Cellswereprimedin96-wellplates(triplicates)withtheindicatedconcentrationsofsolubleTNFfor
18h and were subsequently stimulated with TRAIL (50ng/ml) and Fc-CD95L (MM.1S: 5ng/ml; RPMI8226: 25ng/ml) for an additional 24h before viability was determined by
MTT assay
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Cell Death and Diseasewhether TNF-induced upregulation of CD95 was due to the
activation of the classical NFkB pathway, we took advantage
of the IKK2 inhibitor TPCA-1. The latter allows efﬁcient
inhibition of the classical NFkB pathway but does not
interfere with the activity of the alternative NFkB pathway,
8
which utilizes the IKK2-related kinase IKK1.
5,6 TPCA-1
treatment alone had no effect on basal CD95 expression
but completely abrogated upregulation of CD95 by TNF
(Figure 6a). Moreover, RPMI8226 cells primed with TNF in
the presence of TPCA-1, also failed to respond with an
enhancement of CD95L-induced apoptosis (Figure 6b). TNF
priming in the presence of TPCA-1 resulted in synergistic cell
death induction in MM.1S cells, and thus prevented in this
case analysis of the TNF-CD95L crosstalk (Figure 6c). The
latter ﬁnding could be indicative for a protective effect of
NFkB activity with regard to MM-associated TNF expression.
In fact, IKK2 inhibition also sensitized two of the ﬁve
remaining TNFR1-expressing MM cell lines (OPM2, KMS-
12-BM) analyzed in Figure 1 for TNF-induced cell death
(Figure 6c).
TNFR2 regulates TNFR1-mediated cell death-induction
and TRAF2-related signaling events. The best
investigated aspect of TNFR2 signaling is recruitment of
TRAF2 and the TRAF2-associated proteins, cIAP1 and
cIAP2.
17,18 This results in limited availability of these
proteins for other binding partners, such as the TRAF3-NIK
and the TNFR1 signaling complex.
11 Due to the degradation-
inducing effect of cIAP1 and cIAP2 on TRAF3-associated
NIK,
19,20 TNFR2 stimulation can therefore result in
accumulation of NIK, and subsequent activation of IKK1
and p100 processing thus leading to activation of the
alternative NFkB pathway.
8 In the context of TNFR1
signaling TRAF2-cIAP1/2 complexes are also of pivotal
relevance for activation of the classical NFkB pathway and
in addition prevent RIP1-mediated caspase-8 activation.
7,21
Accordingly, it has been found that TNFR2 activation
antagonizes TNFR1-induced NFkB activation and
enhances cell death induction.
22 In view of the broad
expression of TNFR2 in myeloma cells (Figure 1), we
analyzed whether TNFR2 has similar signaling capabilities
Figure 4 TNF upregulates cell surface expression of CD95. (a) MM.1S and RPMI8226 cells were primed with TNF (50ng/ml) for 18h or remained untreated. Cells were
then treatedin triplicates with the indicatedmixtures of TRAIL (200ng/ml), Fc-CD95L (MM.1S: 30ng/ml; RPMI8226:60ng/ml), zVAD (40mM) and necrostatin-1 (90mM), and
viabilitywasdeterminedafter24hbyMTTstaining.(b)CellsurfaceexpressionofCD95,TRAILR1andTRAILR2ofuntreatedandTNF-primed(200ng/ml,18h)myelomacells
were analyzed by FACS. (c) Untreated and TNF-primed (50ng/ml, 18h) MM.1S and RPMI8226 cells were stimulated for the indicated times with Fc-CD95L (1mg/ml; upper
panel). Untreated and TNF-primed (50ng/ml, 18h) RPMI8226 cells were also stimulated with Fc-scTRAIL (200ng/ml; lower panel). CD95L- and Fc-scTRAIL-associated
proteins were then immunoprecipitated using protein G agarose, and immunoprecipitates and cell lysates were ﬁnally analyzed for the presence of the indicated proteins by
western blotting. Cell lysates supplemented with 10ng of Fc-CD95L or Fc-scTRAIL were immunoprecipitated as negative controls
Figure 5 The differential effect of TNF on CD95L- and TRAIL-induced apoptosis in multiple myeloma cells is mediated by TNFR1. (a) MM.1S and RPMI8226 cells were
primed with 200ng/ml of the TNFR1-speciﬁc mutant Flag-TNF(32W/86T) or the TNFR2-speciﬁc TNF variant Flag-TNC-scTNF(143N/145R) or remained untreated. Cell
surfaceexpressionofCD95(unﬁlledcurves)andIgG1ascontrol(ﬁlledcurves)werethenanalyzedbyFACS.(b)MM.1SandRPMI8226cellswereagainprimedwiththeTNF
receptor-speciﬁc TNF variants (Flag-TNF(32W/86T): 50ng/ml; Flag-TNC-scTNF(143N/145R): 200ng/ml), and were stimulated the next day for 24h with Fc-CD95L (MM.1S:
1ng/ml; RPMI8226: 5ng/ml) and TRAIL (100ng/ml). Viability was determined by MTT assay
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Cell Death and Diseasein myeloma cell lines. Analysis of total cell lysates revealed
that TNFR2 stimulation triggered robust (JJN3, AMO1 and
KMS11) to moderate (RPMI8226, KMS-12-BM, INA6 and
OPM2) TRAF2 degradation in 7 of the 10 investigated cell
lines (Figure 7a). In ﬁve cases this was accompanied by
accumulation of NIK (Figure 7a). Surprisingly, however, none
of the cell lines responded with appreciable p100 processing.
In accordance with the antiapoptotic function of TRAF2 in
TNFR1 signaling, we observed enhanced TNFR1-induced
cell death in JJN3 but not in the other cells (Figure 7b and
data not shown). Thus, although TNFR2 stimulation
signiﬁcantly affected TRAF2 and NIK expression in most
MM cell lines, this resulted only in one case in a
corresponding downstream p100 processing effect.
Discussion
Transcription factors of the NFkB family regulate a variety of
genes required for growth, survival and migration of cells. It is
therefore not surprising that deregulated activation of the
NFkBsystemhasbeenimplicatedincancerdevelopmentand
metastasis. In multiple myeloma, there is evidence that NFkB
activity promotes growth, immortalization and survival of
tumor cells as well as angiogenesis.
23 For example, NFkB-
inhibitory drugs, such as the proteasome inhibitor bortezomib
orIKK2inhibitors, reduce proliferationandenhanceapoptosis
in myeloma cells.
3,24–27 Moreover, two recent studies
demonstrated that more than 80% of myeloma biopsies have
a gene expression signature characteristic for NFkB activity;
andfurthermoreidentiﬁedinaconsiderablefractionofMMcell
lines and patient samples (close to 20%), genetic lesions that
could lead to cell autonomous activation of NFkB signaling.
3,4
TNF is a strong activator of the classical NFkB pathway and is
itself regulated by this pathway.
9 Although increased TNF
levels have consistently been observed in multiple myelo-
ma,
28–32 there are conﬂicting data on an association of high
producer alleles of the TNF and LTa genes with the risk for
multiple myeloma.
31,33–38 Notably, a pilot study in which 10
patients with refractory multiple myeloma received medical
treatment with a soluble TNFR2 fusion protein (Enbrel/
Etanercept) come out with the unexpected result that TNF
plasma levels were signiﬁcantly increased. Moreover, 4 of the
Figure 6 The IKK2 inhibitor TPCA-1 inhibits TNF-induced upregulation of CD95 expression and modulation of TRAIL- and CD95L-induced apoptosis. (a) MM.1S and
RPMI8226 cells were primed with 200ng/ml TNF for 18h in the presence and absence of 10mM TPCA-1. Cell surface expression of CD95 (unﬁlled curves) and IgG1 as
control (ﬁlled curves) were analyzed by FACS. (b) RPMI8226 cells were treated as indicated with TNF (50ng/ml) and TPCA-1 (10mM) for 18h and were challenged the next
day for 24h with TRAIL (200ng/ml) and Fc-CD95L (10ng/ml). Cellular viability was determined with the MTT assay. (c) Cells were stimulated with the indicated mixtures of
TNF (50ng/ml) and TPCA-1 (10mM) and were analyzed for cellular viability after 42h by MTT assay
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Cell Death and Disease10 patients, three with stable and one with progressive
disease at therapy start, showed progressive disease during
therapy.
39 The basis of this counterintuitive increase in TNF in
the presence of Enbrel is unclear but could be related, among
other things, to reverse signaling of membrane TNF or
differential inhibition of soluble and membrane TNF and thus
differential inhibition of TNFR1 and TNFR2 that can elicit
opposing effects on NFkB signaling.
11,40 In any case this pilot
study provides initial evidence that the TNF/TNF receptor
system is not only active in multiple myeloma but also of
signiﬁcance for the course of the disease.
In view of the pivotal role of the classical NFkB pathway for
cell survival, we asked in this study whether TNF modulates
the sensitivity of MM cell lines for apoptosis. First, we
analyzed various myeloma cell lines with respect to the cell
surface expression of the two TNF receptors TNFR1 and
TNFR2. Although TNFR2 expression was found on 9 of 10
cell lines, TNFR1 expression was rather restricted (Figure 1).
TNFR1 is the major receptor involved in TNF-induced
activation of the classical NFkB pathway.
8,9 Therefore, we
initially focused our analysis on MM.1S and RPMI8226 cells
that showed strong TNFR1-mediated NFkB activation in
terms of phosphorylation and degradation of IkBa and
upregulation of NFkB-regulated factors (Figures 2a and b).
TNFR1, CD95 and the two TRAIL death receptors, TRAILR1
and TRAILR2, all belonging to the death receptor subgroup of
the TNF receptor family, signal apoptosis by FADD and
caspase-8.
9,13 Notably, however, while Fc-CD95L and TRAIL
potently induced apoptosis in both cell lines within 18h,
treatmentwithsolubleTNF,thusTNFR1activation,elicitedno
or only a very minor growth inhibitory effect (Figure 3). This
different sensitivity is typically also observable in other cell
types andmight mainly reﬂectthe fact thatTNFR1-associated
caspase-8 activation, in contrast to CD95-, TRAILR1- and
TRAILR2-associated activation of this protein, is not only
inhibited by FLIP proteins but also by TRAF2-cIAP1/2-
containing complexes.
22 Consequently, we and others found
that cytoplasmic deviation of these complexes by recruitment
to TRAF2-cIAP1/2-interacting receptors, such as TNFR2,
results in enhanced TNFR1-induced cell death (for review,
see Naude et al.
22). In accordance with the idea that such
TRAF2-containing complexes are also operative in myeloma
cells, we indeed noticed enhanced TNFR1-induced cell death
in TNFR2-primed JJN3 cells (Figure 7b).
Although activation of the classical NFkB pathway has
frequently been implicated in development of resistance
against chemotherapeutic drugs,
41 we observed no inhibitory
effect of TNF priming on cell death induction by different types
of anti-myeloma drugs despite upregulation of anti-apoptotic
proteins, such as cIAP2 and FLIPL/S (Figures 2b and 4c).
Surprisingly, however, TNF priming elicited opposing effects
on TRAIL- and CD95L-induced cell death (Figures 3b–d),
Figure 7 TNFR2 triggers TRAF2 degradation and NIK accumulation in myeloma cell lines. (a) The indicated myeloma cell lines were stimulated with 200ng/ml of the
TNFR2-speciﬁc TNF variant Flag-TNC-scTNF(143N/145R) for 18h. Whole-cell lysates were subjected to western blot analysis to detect the indicated proteins. (b) JJN3 cells
were primed overnight with 200ng/ml Flag-TNC-scTNF(143N/145R) (open bars) or remained untreated (ﬁlled bars) and challenged the next day with 200ng/ml Flag-
TNF(32W/86T) for 24h. Cell viability was determined by MTT assay
TNF and the extrinsic apoptotic pathway in myeloma cells
H Rauert et al
9
Cell Death and Diseasealthough the corresponding death receptors trigger apoptosis
by the same receptor-associated mechanisms.
13 The latter
suggested that TNF priming acts, at least partly, upstream of
caspase-8 on receptor-proximal steps in TRAIL- and CD95L-
induced apoptosis. Indeed, CD95 and both TRAIL death
receptors as well as the FLIP proteins are regulated by the
classical NFkB pathway in a cell-type-speciﬁc manner.
42–47
FACS analysis, western blotting and immunoprecipitation
experiments revealed that TNFR1 activation enhances cell
surface expression of CD95 but not of the TRAIL death
receptors in myeloma cells (Figures 4b and c). Experiments
using the IKK2 inhibitor TPCA-1 further indicated that the
TNF-induced upregulation of CD95 expression occurred via
the classical NFkB pathway (Figure 6a). Moreover, in
RPMI8226cellsTPCA-1notonlypreventedTNFR1-mediated
upregulation of CD95 (Figure 6a) but also diminished the
enhancing effect of TNF on CD95L-induced apoptosis
(Figure 6b). TNF-mediated sensitization for apoptosis induc-
tion by CD95 upregulation has previously been observed
also in the OH2 myeloma cell line,
48 and NFkB-mediated
CD95 upregulation has recently been found to exert pro-
apoptotic effects in an animal model of cMyc-induced
lymphomagenesis.
49
Although the IKK2-mediated upregulation of CD95 explains
why TNF priming sensitizes for CD95L, but not for TRAIL-
induced apoptosis, it does not provide an answer for the
mechanism(s) underlying the protective effect of TNF priming
against TRAIL. The most relevant protective factors regulated
by NFkB in the context of death receptor signaling are
certainly the FLIP proteins. The different isoforms of FLIP
corecruit with caspase-8 to the TRAIL death receptors and
CD95 where they interfere with caspase-8 maturation.
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Analysis of cell lysates and immunoprecipitates of CD95
and TRAIL receptors of TNF-primed MM cells indeed
revealed upregulation of FLIP (Figure 4c). Moreover, in
accordance with an increased inhibitory effect of FLIP
proteins on TRAIL-induced apoptosis in TNF-primed cells,
there was reduced processing of the long isoform of FLIP in
the TRAIL-associated receptor signaling complex as well as
increased recruitment of this protective factor (Figure 4c).
In sum, these data suggest the following model (Figure 8):
activation of the classical NFkB pathway via TNFR1 results in
the upregulation of CD95 and FLIP proteins. With respect to
TRAIL signaling only the latter is of relevance and has a
protective effect. In case of CD95 signaling, however, there
are two opposing effects, moderate upregulation of FLIP and
strong upregulation of CD95, the net effect of which is
enhanced CD95-mediated apoptosis.
In this study we identiﬁed multiple mechanisms by which
TNF and its receptors regulate the sensitivity of myeloma cell
lines for extrinsic apoptosis. In view of the quite variable
expression of the two TNF receptors in the different myeloma
cell linesandthe knownheterogeneityofgenetic alterationsin
multiple myeloma, it should not be surprising that these
mechanisms are not equally effective in all cell lines
investigated but rather occur in each case only in a subset
of the cell lines. A major difference between primary myeloma
samples and myeloma cell lines is the much higher
proliferative capacity of the latter. It is thus desirable to
recapitulate ﬁndings obtained from experiments with cell lines
with primary myeloma cells. Biopsies of patients suffering
from multiple myeloma typically contain very limited numbers
of cells (10
5–10
6) and their clinical frequency is rather
moderate. Analysis of primary myeloma samples is therefore
more practicable for the investigation of processes occurring
in a large fraction of primary samples and requiring only a low
number of experimental groups. However, this approach is
poorly feasible for investigations of scenarios like those
studied in this study that possibly occur only in a fraction of
samples and requires the parallel analysis of several groups
(e.g. plus/minus TNF, plus/minus CD95 stimulation, plus/
minus IKK2 inhibition) by two or more parameters (e.g. cell
surface receptor expression and apoptosis assay). Thus, a
future challenge will be to evaluate the relevance of TNF and
its receptors for the development and treatment of multiple
myleoma in animal models of this disease.
Materials and Methods
Cell lines, reagents and antibodies. HEK293, MM.1S, RPMI8226,
AMO1, U266, L363, JJN3, OPM2, KMS-12-BM, KMS-11 and INA6 cells were
maintainedinRPMI1640medium(PAA,Pasching,Germany),containing10%heat-
inactivated fetal bovine serum (PAA). For INA6 cells the culture medium was
supplemented with recombinant human IL6 (10ng/ml, ImmunoTools, Friesoythe,
Germany). Mutations conferring speciﬁcity for TNFR1 and TNFR2 to soluble TNF
have been described elsewhere by Loetscher et al.
10 The various Flag-tagged
variantsof solubleTNFor CD95Lused inthis study wereproducedin HEK293cells
and puriﬁed by afﬁnity chromatography on anti-Flag mAb M2-agarose. The pan-
caspase inhibitor, zVAD, was purchased from Bachem (Weil am Rhein, Germany).
Necrostatin-1, anti-FLIP (NF6, 804-428-C100) and TRAIL were from Enzo Life
Sciences (Lo ¨rrach, Germany). TRAF2-speciﬁc antibody (H-249 and sc-7187), anti-
IkBa (FL and sc-847), anti-CD95 (C-20 and sc-715) and anti-FADD (H-181 and
sc-5559) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Anti-tubulin (DM1A and MS-581-P) was from Neomarkers (Fremont, CA, USA),
anti-p100 (05-361) from Millipore (Temecula, CA, USA), anti-cIAP2 (51-9000062)
was from BD (Heidelberg, Germany), and anti-NIK (4994), anti-rabbitHRP (7074)
and anti-pIkBa (S32, 2859L) were from Cell Signaling Technologies (Danvers, MA,
USA). Anti-mouseHRP (p0260) and anti-rabbitHRP (p0448) were from Dako
(Hamburg, Germany). Anti-caspase-8 was a kind gift of Prof. K. Schulze-Osthoff
(University of Tu ¨bingen, Germany). The IKK2 inhibitor TPCA-1 was from Tocris
Bioscience (Ellisville, MO, USA) and Akti-1/2 from Merck (Darmstadt, Germany).
Protein G-agarose was from Roche (Mannheim, Germany). The phycoerythrin-
conjugated antibodies anti-TNFR1(FAB225P), anti-TNFR2 (FAB226P), anti-
TRAILR1 (FAB347P), anti-TRAILR2 (FAB6311P), anti-IgG1 (IC002P), anti-IgG2a
(IC003P), and IgG2b (IC0041P) and the ﬂuorescein isothiocyanate-conjugated
Figure 8 Model of the differential regulation of CD95L- and TRAIL-induced
apoptosis by TNFR1. TNFR1-induced activation of the classical NFkB pathway
results in concomitant upregulation of FLIPL/S and CD95. Although upregulation of
FLIPL/S antagonizes TRAIL-induced apoptosis, this effect is overcompensated in
context of CD95L-induced signaling by the strong increase in CD95 expression
TNF and the extrinsic apoptotic pathway in myeloma cells
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Cell Death and Diseaseanti-CD95 (FAB142F) and anti-IgG1 (IC002F) were from R&D Systems
(Wiesbaden-Nordenstadt, Germany).
Flow cytometry. Cells were stained with phycoerythrin- or ﬂuorescein
isothiocyanate-conjugated monoclonal antibodies speciﬁc for TNFR1, TNFR2,
CD95, TRAILR1 and TRAILR2 or with corresponding isotype control antibodies for
20minonice,andaftertwowasheswithPBScellswereanalyzedbyﬂowcytometry
using a FACS ﬂow cytometer and the corresponding software supplied by the
manufacturer (BD Calibur, BD, Heidelberg, Germany).
Binding studies with Gaussia princeps luciferase TNF fusion
proteins. Cells (3 10
6) were incubated with either the TNFR1-speciﬁc mAb
H398 (10mg/ml) (a kind gift of Profs. K. Pﬁzenmaier and P. Scheurich, University of
Stuttgart,Germany)oramixtureof3mg/ml Flag-TNC-scTNF(143N/145R) and3mg/ml
Flag-TNF for 1h on ice or left untreated. Cells were then incubated for anotherhour
on ice with TNFR1- (200ng/ml) or TNFR2- (100ng/ml) speciﬁc Gaussia princeps
luciferase fusion proteins of Flag-TNC-TNF(32W/86T) and Flag-TNC-scTNF(143N/
145R).Toremoveunboundligand,cellswerewashedthreetimeswithice-coldPBS
andweresuspendedin50mlculturemediumwith0.5%FBSinablack96-wellplate.
Luciferase activity was determined by using a Luciferase Assay Kit (New England
BiolabsGmbH,Frankfurta. M.,Germany)andmeasuredina Luminometer (Lucy2,
Anthos Labtec Instruments, Wals/Salzburg, Austria). Speciﬁc binding is the
difference of total binding (i.e. luciferase activity of cells treated with the luciferase
fusion proteins alone) and non-speciﬁc binding (i.e. the activity of samples which
were pre-incubated with H398 or a mixture of Flag-TNC-scTNF(143N/145R) and
Flag-TNF as blocking reagents).
Death-inducing signaling complex analysis. Cells (70 10
6 in 5ml)
were stimulated with Fc-CD95L (1mg/ml) or Fc-scTRAIL (200ng/ml) for the
indicated times at 371C or remained untreated. After two washes with ice-cold
phosphate-buffered saline, cells were lysed by incubation (20min on ice) in 1.5ml
lysis buffer (30mM Tris-HCl, pH 7.5, 1% Triton X-100, 10% glycerol and 120mM
NaCl) supplemented with complete protease inhibitor cocktail (Roche). Lysates
were cleared by centrifugation (30min, 14.000 g), and Fc-CD95L/Fc-scTRAIL-
associated proteins were precipitated with protein G agarose beads (Roche; 20ml
of a 50% slurry, overnight at 41C). As a control, lysates of unstimulated cells
were supplemented with 10ng of the corresponding ligand and subjected to
immunoprecipitation with protein G beads. Immuncomplexes were washed ﬁve
times with ice-cold lysis buffer, and bound proteins were eluted by incubation at
701C for 10min in 4 Laemmli buffer and analyzed by western blotting.
Western blotting. For western blot analysis of whole cell lysates, cells were
lysed in 4 Laemmli sample buffer which was supplemented with complete
protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktail II (Sigma-
Aldrich, Munich, Germany). Upon soniﬁcation, samples were heated (5min, 961C)
and subjected to protein separation by SDS-PAGE. Proteins were transferred to
nitrocellulose membranes by semi-dry blotting and remaining binding sites were
blocked by incubation with PBS or TBS containing 0.05% Tween 20 and 5% dry
milk. To detect the proteins of interest, membranes were incubated over night with
corresponding primary antibodies. To ﬁnally visualize bound primary antibodies,
membranes were incubated with horseradish peroxidase-conjugated secondary
antibodies and the obtained antibody-containing complexes were detected with the
ECL Western blotting detection system (Pierce, Thermo Fischer Scientiﬁc, Bonn,
Germany).
Determination of cellular viability. The various multiple myeloma cell
lineswereplatedintoa96-wellplateandwerechallengedwiththevariousstimulias
indicated in the corresponding ﬁgure legends. Metabolically active cells were ﬁnally
quantiﬁed using a standard MTT protocol. Viability was calculated as percentage of
the viability of untreated cells (100% viability). Background staining of completely
killed cells (0% viability) was determined using a group consisting of cells that had
been exposed to a deadly mixture containing CHX, TRAIL and Fc-CD95L.
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